Clinical Trials Browser

INDUSTRY × Has announcements × durvalumab × Clear all

NCT03298451 2026-03-20

HIMALAYA

Phase 3 Active not recruiting

1,324 enrolled 31 charts 2 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT03875235 2026-03-19

TOPAZ-1

Phase 3 Active not recruiting

810 enrolled 24 charts 2 FDA

Gastrointestinal

Biliary Tract Neoplasms

NCT03164616 2026-03-13

POSEIDON

Phase 3 Active not recruiting

1,186 enrolled 26 charts 2 FDA

Non Small Cell Lung Cancer NSCLC

NCT03732677 2026-03-13

NIAGARA

Phase 3 Active not recruiting

1,063 enrolled 15 charts 3 FDA

Urinary Bladder Neoplasms

NCT04592913 2025-12-24

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

Phase 3 Active not recruiting

957 enrolled 3 FDA

Gastrointestinal

Gastrointestinal Neoplasms

NCT04269200 2025-12-23

DUO-E

Phase 3 Active not recruiting

805 enrolled 18 charts 2 FDA

Endometrial Neoplasms

NCT03703297 2025-11-21

ADRIATIC

Phase 3 Active not recruiting

730 enrolled 19 charts 3 FDA

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03043872 2025-10-21

CASPIAN

Phase 3 Active not recruiting

987 enrolled 42 charts 3 FDA

Small Cell Lung Carcinoma

NCT03800134 2025-06-11

AEGEAN

Phase 3 Active not recruiting

825 enrolled 3 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03737643 2025-01-29

DUO-O

Phase 3 Active not recruiting

1,407 enrolled 3 FDA

Ovarian Neoplasms

NCT02125461 2023-10-10

PACIFIC

Phase 3 Completed

713 enrolled 23 charts 2 FDA

Carcinoma, Non-Small-Cell Lung